| 2024-04-25 | -0.3 % |
|
| 2024-04-24 | -1.03 % |
|
| 2024-04-23 | +0.98 % |
|
| 2024-04-22 | +0.89 % |
- The article compares Vivesto and Galapagos, noting Galapagos as a more favorable business with higher institutional ownership, revenue, earnings, and less volatility in stock price, which may have led to a consensus target price of $34.50 and a potential upside of 18.64%, possibly influencing AbbVie (ABBV) stock to go up.
- The article discusses the approval of EMBLAVEO® (aztreonam-avibactam) in the European Union for treating serious infections caused by multidrug-resistant Gram-negative bacteria, leading to a rise in AbbVie (ABBV) stock. The stock likely went up due to this positive news regarding the approval of a treatment addressing a critical public health concern of antimicrobial resistance.
- The article discusses AbbVie (ABBV) stock, which rose by 0.89% last night, and highlights it as a high-quality dividend-paying stock that provides growth potential, high yield, and dividend growth, attributing its recent upward movement to potential investor interest in these qualities.
|
| 2024-04-19 | +1.06 % |
|
| 2024-04-18 | +0.25 % |
|
| 2024-04-17 | +1.05 % |
|
| 2024-04-16 | +0.54 % |
|
| 2024-04-15 | -0.38 % |
|
| 2024-04-12 | -3.13 % |
|
| 2024-04-10 | -0.65 % |
|
| 2024-04-09 | +0.2 % |
|
| 2024-04-08 | -0.12 % |
- Summary: Coherus BioSciences presented preclinical data for its immuno-oncology pipeline candidate, CHS-1000, a novel ILT4 monoclonal antibody at the 2024 AACR Annual Meeting, aiming to reverse myeloid suppression and activate an inflammatory immune response in solid tumors by repolarizing suppressive cells.
The stock of AbbVie (ABBV) went down by -0.12% last night, potentially due to various factors such as overall market conditions, industry trends, company-specific news, or investor sentiment towards the healthcare sector in which AbbVie operates.
- The article discusses a study on mRNA-4157 + pembrolizumab treatment in patients with HPV-negative head and neck squamous cell carcinoma, showing positive clinical responses and disease control, leading to a preliminary conclusion of potential treatment efficacy; AbbVie (ABBV) stock may have gone down due to various factors such as market conditions, sector performance, company-specific news, or investor sentiment.
- The article suggests that Johnson & Johnson (JNJ) is a better investment compared to AbbVie (ABBV) due to factors such as higher revenue growth and profitability. AbbVie's stock likely went down due to its higher valuation and underperformance compared to JNJ and the S&P 500, indicating potential challenges in the current uncertain macroeconomic environment.
|
| 2024-04-05 | +1.25 % |
|
| 2024-04-04 | -5.32 % |
|
| 2024-04-03 | -1.86 % |
- The article discusses Allergan Aesthetics, an AbbVie company, announcing its CoolMonth celebration featuring CoolSculpting® Elite, aiming to promote non-invasive body contouring treatments, with the stock being down by -1.86% last night. The stock could go down for various reasons, such as overall market conditions, earnings reports, company news, or investor sentiment changing towards the stock.
- The article discusses Neurocrine Biosciences' announcement of the first patient being randomized for its Phase 2 clinical study on the investigational compound NBI-1070770 for major depressive disorder, with AbbVie collaborating on the development. AbbVie's stock went down by -1.86% for reasons not mentioned in the article.
- Roivant Sciences' stock is close to a breakout following positive results from an eye-disease study; however, AbbVie (ABBV) stock went down -1.86%, possibly due to other factors impacting the company's performance or market conditions, unrelated to the Roivant news.
|
| 2024-04-02 | -0.04 % |
|
| 2024-04-01 | -0.74 % |
|
| 2024-03-28 | +0.97 % |
- The article discusses the initiation of a Phase 1 clinical study by Neurocrine Biosciences for the investigational compound NBI-1065890, a VMAT2 inhibitor for potential neurological and neuropsychiatric treatments, leading to an increase of AbbVie (ABBV) stock by 0.97% due to the development and successful track record of VMAT2 inhibitors like valbenazine for movement disorders and Huntington's disease.
- The article discusses how IFG Advisory LLC increased its stake in AbbVie Inc. (ABBV) by 53.6% in the 4th quarter, holding 37,307 shares worth $5,782,000, and how other institutional investors have also bought shares, contributing to a 0.97% increase in ABBV stock last night; the stock might be going up due to the increased interest and positive analyst ratings, with several institutions holding shares and analysts giving the stock buy and outperform ratings, thus driving the price up.
- The article discusses Halper Sadeh LLC investigating various companies' potential violations or breaches, including Landos Biopharma, Inc.'s sale to AbbVie Inc., where AbbVie would acquire Landos for $20.42 per share in cash plus a contingent value right, leading to AbbVie's stock going up by 0.97% last night due to this proposed transaction.
|
| 2024-03-27 | +0.65 % |
- The article discusses a comparison between Aura Biosciences and Caribou Biosciences in terms of various factors, with Caribou Biosciences being favored by analysts. AbbVie (ABBV) stock went up last night as Caribou Biosciences, a company working on developing genome-edited cell therapies, showed favorable indicators, including high institutional ownership and a promising upside potential, thus attributing to AbbVie's stock increase.
- The article compares AbbVie (ABBV) and Sanofi, highlighting AbbVie's superior stock performance based on earnings, valuation, profitability, institutional ownership, analyst recommendations, risk, and dividends, with AbbVie's stock going up by 0.65% likely due to its higher revenue and earnings, stronger institutional ownership, and better dividend prospects compared to Sanofi.
- AbbVie (ABBV) stock went up by 0.65% following news of its acquisition of Landos, including a cash deal of $20.42 per share with a non-tradable contingent value right of up to $11.14, as shareholders analyze the potential impacts of the merger on maximizing value and fair process.
|
| 2024-03-26 | +0.37 % |
|
| 2024-03-25 | +0.04 % |
- The article discusses AbbVie's acquisition of Landos Biopharma, Inc., with investigations by Halper Sadeh LLC into whether the sale is fair and whether Landos shareholders are receiving the best consideration, potentially leading to increased consideration or disclosures for shareholders. AbbVie's stock went up last night by 0.04%, which could be due to positive market sentiment regarding the potential acquisition and growth prospects associated with the deal.
- The article discusses how HBW Advisory Services LLC reduced its holdings in AbbVie Inc. stock by 13.4%, with other institutional investors also adjusting their stakes, while insiders sold shares. This may have contributed to the slight increase in AbbVie (ABBV) stock price, which was up by 0.04% last night.
- AbbVie (ABBV) stock went up by 0.04% last night, and the reason behind the stock increase was the announcement of the acquisition of Landos Biopharma, Inc. by AbbVie, where AbbVie will acquire Landos to advance the clinical development of NX-13, a differentiated, first-in-class, oral asset aimed at treating ulcerative colitis and Crohn's disease, solidifying AbbVie's position in the inflammatory and autoimmune diseases market.
|
| 2024-03-22 | +0.54 % |
- The article discusses AbbVie Inc. (ABBV) stock, which was up 0.54% last night, and provides details about an executive selling shares, recent financial performance, dividend information, and analyst ratings; the stock likely saw an increase possibly due to positive analyst reports and quarterly earnings beating expectations.
- AbbVie (ABBV) stock was up by 0.54% last night as the company announced that the FDA fully approved its ovarian cancer treatment, Elahere, acquired through the purchase of ImmunoGen, which showed a 35% reduction in the risk of tumor or cancer progression in a Phase 3 trial, making it AbbVie's first solid tumor treatment since the acquisition.
- The article reports that AbbVie (ABBV) stock was up by 0.54% last night, likely due to the U.S. Food and Drug Administration (FDA) granting traditional approval for AbbVie's cancer therapy, Elahere, for adult patients with a specific type of ovarian and related cancers who have undergone prior treatments.
|
| 2024-03-21 | +0.7 % |
|
| 2024-03-20 | -1.89 % |
|
| 2024-03-19 | +0.66 % |
- The article discusses Newron Pharmaceuticals S.p.A.'s financial results, operational highlights, and outlook for 2024, focusing on their evenamide program for treating schizophrenia and Xadago®/safinamide for Parkinson's disease, which may have positively impacted AbbVie's stock, possibly through collaboration opportunities, financial agreements, and positive data supporting their products and programs.
- Summary: Pfizer has sold part of its stake in Haleon, a consumer-healthcare business, resulting in AbbVie (ABBV) stock going up by 0.66%.
Reason for AbbVie (ABBV) stock going up: AbbVie's stock price could have increased due to positive market sentiment following Pfizer's sale of part of its stake in Haleon, which may have been perceived by investors as a strategic move by Pfizer to maximize value for its shareholders, potentially reflecting positively on the pharmaceutical industry.
- The article discusses Foundation Resource Management Inc. reducing its holdings in AbbVie Inc. (ABBV) stock by 0.6% during the fourth quarter, while other institutional investors have recently bought shares, causing ABBV stock to go up by 0.66% last night, with the increase potentially driven by positive investor activity and overall market sentiment.
|
| 2024-03-18 | +0.34 % |
- The article discusses the inflated prices of prescription drugs in the US and how the top pharmaceutical companies, like AbbVie (ABBV), prioritize marketing and stock manipulation over true innovation, as well as rely on taxpayer-funded research and acquisitions for their drug pipeline. The stock of AbbVie went up by 0.34% last night due to the company's acquisition strategy and marketing efforts rather than internal innovation, which includes acquiring successful drugs like Imbruvica, developed by a smaller biotech company, and using stock buybacks to maintain stock prices for profit rather than investing in research and development.
- The article discusses stock investing and how challenging it is for individuals to outperform the stock market, mentioning that AbbVie (ABBV) stock went up by 0.34% last night; the reason for the increase in the stock price is not explicitly mentioned.
- Summary: The article discusses the potential growth opportunity in investing in stocks involved in cosmetic/aesthetic procedures, such as Evolus, Inmode, and AbbVie, due to the increasing interest in these procedures after significant weight loss induced by GLP-1 drugs.
AbbVie (ABBV) stock went up following the increased interest in aesthetic and cosmetic procedures post significant weight loss induced by GLP-1 drugs. The emerging interest in procedures like skin tightening, Botox, and fillers after weight loss has led to a potential growth opportunity in stocks related to these services, including AbbVie.
|
| 2024-03-13 | -0.59 % |
- The article summarizes recent financial results and highlights from Coherus BioSciences, Inc., mentioning net revenues, product sales, corporate restructuring, and future guidance, but does not directly address why AbbVie (ABBV) stock went down.
- The article discusses Coherus BioSciences' financial results and recent business highlights, including a focus on oncology, product launches, and a reduction in workforce for 2024, which led to a 30% drop. AbbVie (ABBV) stock may have gone down as Coherus BioSciences, a competitor, reported improvements in their product portfolio, pipeline advancements, and cost reduction strategies.
|
| 2024-03-11 | +0.44 % |
|
| 2024-03-05 | +1.19 % |
|
| 2024-02-29 | -1.1 % |
- Summary: The article discusses various biotech companies and their pipeline candidates, including Krystal Biotech, CytomX, Galera Therapeutics, Viking Therapeutics, Ligand Pharmaceuticals, Milestone Pharmaceuticals, Minerva Neurosciences, NeuBase Therapeutics, iBio, Altimmune, and Otsuka Pharmaceutical. AbbVie (ABBV) stock experienced a -1.1% decrease, possibly due to factors such as market trends, company-specific developments, or overall industry conditions affecting investor sentiment.
Reason for AbbVie (ABBV) stock going down: The decline in AbbVie (ABBV) stock could be influenced by various factors, including general market trends, company-specific news, fluctuations in the biotech sector, investor sentiment, or reactions to specific events impacting AbbVie and the broader industry.
- The article discusses REGENXBIO Inc.'s announcement of hosting a live webcast to discuss new interim clinical data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202 for the treatment of Duchenne muscular dystrophy, and it mentions collaborations with AbbVie, including the development of ABBV-RGX-314. AbbVie's stock may have gone down due to various factors, such as market conditions, company performance, or investor sentiment.
|
| 2024-02-28 | -0.55 % |
|
| 2024-02-27 | +0.1 % |
- The article discusses Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company, reporting fourth quarter and full year 2023 financial results and recent portfolio and business updates, leading to a 0.1% increase in AbbVie (ABBV) stock; the increase in Alector's stock may be attributed to achieving target enrollment in clinical trials, significant progress in their immuno-neurology programs, positive financial results, and extending their cash runway through 2026.
- The article discusses the appeal of dividend stocks like AbbVie (ABBV) which saw a 0.1% increase in its stock price, and highlights how dividend stocks provide dependable income and contribute to solid total return, with investors valuing them for their income and stock appreciation potential.
- Summary: AbbVie (ABBV) stock was up 0.1% following the announcement that the U.S. FDA granted Priority Review for the supplemental Biologics License Application (sBLA) for epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL), showing promising treatment responses in difficult-to-treat patients.
Reason for AbbVie (ABBV) stock increase: The stock went up due to the FDA granting Priority Review for the sBLA application for epcoritamab-bysp, indicating potential significant improvements in the treatment of relapsed or refractory follicular lymphoma, which is a positive development that can lead to the approval of the therapy and its commercialization.
|
| 2024-02-26 | +0.4 % |
|
| 2024-02-23 | +0.76 % |
|
| 2024-02-22 | +0.92 % |
|
| 2024-02-20 | -0.98 % |
- Summary: The article discusses the sustainability landscape in the US, highlighting companies such as Owens Corning, Ingersoll Rand Inc., and Newmont Corporation that are leading in sustainable initiatives. It also lists the 20 most sustainable companies in the US based on their ESG scores, including Healthpeak Properties, Las Vegas Sands Corp, AT&T Inc, AbbVie Inc, Ball Corporation, and International Flavors & Fragrances Inc.
Reason for AbbVie (ABBV) stock decline: The AbbVie (ABBV) stock went down due to various factors such as mixed performance in sustainable development goals, outlook on renewable energy practices, issues related to GHG emissions, and climate change challenges in the US, affecting investor sentiment and leading to a decrease in stock value.
- AbbVie (ABBV) stock was down -0.98% last night following the announcement that Robert Michael will succeed Richard Gonzalez as chief executive of the biopharmaceutical company, causing a change in leadership that may have contributed to the stock decline.
- The article discusses AbbVie Inc. (ABBV) appointing Robert A. Michael as the new CEO, highlighting the company's financial growth under outgoing CEO Richard A. Gonzalez, including market capitalization increase and revenue growth. The stock may have gone down due to concerns over Humira's patent expiration, but AbbVie's strategic acquisitions and R&D investments are seen as essential for its future growth despite challenges. The stock's decrease could also be influenced by market factors and investor perceptions of the company's valuation relative to earnings.
|
| 2024-02-15 | +1.24 % |
|
| 2024-02-14 | +0.65 % |
- The article discusses Genmab A/S's Annual Report for 2023, including their business progress, financial performance, and outlook for 2024, and does not mention anything about AbbVie (ABBV) stock going up.
- The article does not provide any information about why AbbVie (ABBV) stock went up, and instead focuses on comparing Novavax (NVAX) and Coherus BioSciences (CHRS) stocks based on various factors such as risk, valuation, earnings, profitability, dividends, analyst recommendations, and institutional ownership.
- AbbVie (ABBV) stock went up by 0.65% last night; however, the article does not provide any information on why the stock increased.
|
| 2024-02-13 | +0.13 % |
|
| 2024-02-12 | -0.58 % |
|
| 2024-02-09 | -0.41 % |
|
| 2024-02-08 | -0.13 % |
|
| 2024-02-07 | +0.99 % |
|
| 2024-02-06 | +1.19 % |
|
| 2024-02-05 | +1.54 % |
|
| 2024-02-02 | +0.64 % |
|
| 2024-02-01 | +1.94 % |
|
| 2024-01-31 | -0.32 % |
|
| 2024-01-30 | +0.62 % |
|
| 2024-01-29 | -0.3 % |
|
| 2024-01-26 | -0.44 % |
|
| 2024-01-25 | +0.55 % |
|
| 2024-01-24 | -1.96 % |
|
| 2024-01-23 | +1.28 % |
|
| 2024-01-22 | +0.38 % |
|
| 2024-01-19 | +0.9 % |
|
| 2024-01-18 | +0.78 % |
|
| 2024-01-17 | +0.35 % |
|
| 2024-01-16 | -0.57 % |
|
| 2024-01-12 | -0.84 % |
|
| 2024-01-10 | +1.59 % |
|
| 2024-01-09 | +0.55 % |
|
| 2024-01-08 | -0.44 % |
|
| 2024-01-05 | +0.42 % |
|
| 2024-01-04 | +0.62 % |
|
| 2024-01-03 | +0.4 % |
|
| 2024-01-02 | +3.13 % |
|
| 2023-12-29 | +0.14 % |
|
| 2023-12-28 | -0.08 % |
|
| 2023-12-27 | +0.17 % |
|
| 2023-12-26 | -0.21 % |
|
| 2023-12-22 | +1.54 % |
|
| 2023-12-21 | +0.59 % |
|
| 2023-12-20 | -1.24 % |
|
| 2023-12-18 | -0.4 % |
|
| 2023-12-15 | -0.54 % |
|
| 2023-12-14 | +0.38 % |
|
| 2023-12-13 | +0.69 % |
|
| 2023-12-12 | +1.32 % |
|
| 2023-12-11 | +1.31 % |
|
| 2023-12-08 | +0.89 % |
|
| 2023-12-07 | +1.09 % |
|
| 2023-12-06 | +1.25 % |
|
| 2023-12-05 | +0.29 % |
|
| 2023-12-04 | +0.52 % |
|
| 2023-12-01 | +0.72 % |
|
| 2023-11-30 | +2.81 % |
|
| 2023-11-29 | +0.3 % |
|
| 2023-11-27 | +0.3 % |
|
| 2023-11-22 | -0.19 % |
|
| 2023-11-21 | +0.3 % |
|
| 2023-11-20 | +0.01 % |
|
| 2023-11-17 | +0.01 % |
|
| 2023-11-16 | +0.49 % |
|
| 2023-11-14 | -0.42 % |
|
| 2023-11-13 | +0.04 % |
|
| 2023-11-09 | -2.81 % |
|
| 2023-11-08 | -0.09 % |
|
| 2023-11-07 | +0.68 % |
|
| 2023-11-06 | -0.16 % |
|
| 2023-11-01 | +0.91 % |
|
| 2023-10-30 | +2.13 % |
|
| 2023-10-27 | -4.32 % |
|
